copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
New colorectal cancer treatment approved in the U. S. - Takeda OSAKA, Japan and CAMBRIDGE, Massachusetts, November 8, 2023 – Takeda (TSE:4502 NYSE:TAK) today announced that the U S Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin
FRUZAQLA® (fruquintinib) for Previously Treated mCRC For adults with metastatic colorectal cancer (mCRC), FRUZAQLA is an innovative and convenient oral treatment with proven survival results that can be taken after chemotherapy and other anti-cancer medications FRUZAQLA is a targeted therapy for people living with previously treated mCRC FRUZAQLA is not chemotherapy
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not . . . - Takeda FRUZAQLA can cause serious hemorrhagic events, which may be fatal In 911 patients with mCRC treated with FRUZAQLA, 6% of patients experienced a gastrointestinal hemorrhage, including 13 patients (1%) with a Grade ≥3 event and 2 patients with fatal hemorrhages Permanently discontinue FRUZAQLA in patients with severe or life-threatening
FRUZAQLA® (fruquintinib) Access Guide Please see page 3 for information about Takeda Oncology Here2Assist® Access Guide INDICATION FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an
Fruzaqla (fruquintinib): Prescribing Information, Dosage Side Effects . . . FRUZAQLA (fruquintinib) capsules for oral administration contain 1 mg or 5 mg of fruquintinib The inactive ingredients are corn starch, microcrystalline cellulose, and talc The 1 mg capsule shell contains FD C Yellow No 5 (tartrazine), FD C Yellow No 6 (sunset yellow FCF), gelatin, and titanium dioxide Takeda Live Chat
FRUZAQLA | Oncology | US Site - Takeda Pharmaceutical Company [Fruzaqla 1mg CAP 21Ct USA] (capsule for oral use - 1mg capsule available in bottle of 21 capsules) SKU 6511380 Category Oncology FRUZAQLA [Fruzaqla 5mg CAP 21Ct USA] If you are interested in ordering from Takeda's product offerings, please contact Customer
New colorectal cancer treatment approved in the U. S. - Takeda Oncology Please see FRUZAQLA (fruquintinib) full Prescribing Information About CRC CRC is a cancer that starts in either the colon or rectum According to the International Agency for Research on Cancer, CRC is the third most prevalent cancer worldwide, associated with more than 935,000 deaths in 2020 7 In the U S , it is estimated that 153,000 patients will be diagnosed with CRC and 53,000 deaths
FRUZAQLA Receives European Commission Approval for Metastatic . . . - Takeda Takeda Receives U S FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer [Press Release] Available here Dasari NA, et al Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study Lancet